CENTANY Drug Patent Profile
✉ Email this page to a colleague
When do Centany patents expire, and when can generic versions of Centany launch?
Centany is a drug marketed by Padagis Us and is included in one NDA.
The generic ingredient in CENTANY is mupirocin. There are sixteen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the mupirocin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Centany
A generic version of CENTANY was approved as mupirocin by PADAGIS ISRAEL on November 7th, 2003.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CENTANY?
- What are the global sales for CENTANY?
- What is Average Wholesale Price for CENTANY?
Summary for CENTANY
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 87 |
| Clinical Trials: | 2 |
| Patent Applications: | 5,308 |
| What excipients (inactive ingredients) are in CENTANY? | CENTANY excipients list |
| DailyMed Link: | CENTANY at DailyMed |
Recent Clinical Trials for CENTANY
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Texas Southwestern Medical Center | Phase 2 |
| National Jewish Health | Phase 2 |
| University of North Carolina, Chapel Hill | Phase 2 |
US Patents and Regulatory Information for CENTANY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Padagis Us | CENTANY | mupirocin | OINTMENT;TOPICAL | 050788-001 | Dec 4, 2002 | BX | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CENTANY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Padagis Us | CENTANY | mupirocin | OINTMENT;TOPICAL | 050788-001 | Dec 4, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CENTANY
See the table below for patents covering CENTANY around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Germany | 69900561 | ⤷ Sign Up | |
| Canada | 2259764 | COMPOSITIONS PHARMACEUTIQUES RENFERMANT DE LA MUPIROCINE (PHARMACEUTICAL COMPOSITIONS CONTAINING MUPIROCIN) | ⤷ Sign Up |
| Spain | 2165723 | ⤷ Sign Up | |
| Israel | 123143 | PHARMACEUTICAL COMPOSITIONS CONTAINING MUPIROCIN | ⤷ Sign Up |
| European Patent Office | 0933081 | Compositions pharmaceutiques contenant mupirocine (Pharmaceutical compositions containing mupirocin) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
